Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 1 of the 24 sources its claims cite were checked for support.
Abstract
Epigenetic modifiers have fundamental roles in defining unique cellular identity through the establishment and maintenance of lineage-specific chromatin and methylation status. Several DNA modifications such as 5-hydroxymethylcytosine (5hmC) are catalysed by the ten eleven translocation (Tet) methylcytosine dioxygenase family members, and the roles of Tet proteins in regulating chromatin architecture and gene transcription independently of DNA methylation have been gradually uncovered. However, the regulation of immunity and inflammation by Tet proteins independent of their role in modulating DNA methylation remains largely unknown. Here we show that Tet2 selectively mediates active repression of interleukin-6 (IL-6) transcription during inflammation resolution in innate myeloid cells, including dendritic cells and macrophages. Loss of Tet2 resulted in the upregulation of several inflammatory mediators, including IL-6, at late phase during the response to lipopolysaccharide challenge. Tet2-deficient mice were more susceptible to endotoxin shock and dextran-sulfate-sodium-induced colitis, displaying a more severe inflammatory phenotype and increased IL-6 production compared to wild-type mice. IκBζ, an IL-6-specific transcription factor, mediated specific targeting of Tet2 to the Il6 promoter, further indicating opposite regulatory roles of IκBζ at initial and resolution phases of inflammation. For the repression mechanism, independent of DNA methylation and hydroxymethylation, Tet2 recruited Hdac2 and repressed transcription of Il6 via histone deacetylation. We provide mechanistic evidence for the gene-specific transcription repression activity of Tet2 via histone deacetylation and for the prevention of constant transcription activation at the chromatin level for resolving inflammation.
Overview
CoChat Summary
TL;DR
Tet2 actively represses Il6 transcription during the late phase of LPS-driven inflammation in myeloid cells by recruiting Hdac2 to the Il6 promoter, independent of DNA methylation. Tet2 loss prolongs IL-6 production and worsens endotoxin shock and DSS-induced colitis in mice.
Key findings
- In Tet2-deficient or Tet2-silenced dendritic cells and macrophages, the early LPS-induced rise in Il6 mRNA before 4 h was largely unchanged, but after 8 h Il6 mRNA remained elevated while control cells declined; IL-6 protein also increased, whereas Tnfa levels were similar. Tet3 silencing barely affected Il6.
- Tet2-deficient mice produced more IL-6 after systemic LPS, especially late, and showed worse lung tissue damage; in DSS colitis they had greater weight loss, higher IL-6, more inflammatory cell infiltration, and mucosal disruption. In Tet2-deficient BMDC, 22 genes were downregulated and 13 upregulated; 12 of the upregulated genes were TLR-induced, including Il6.
- IκBζ interacted with Tet2 and was required for Tet2 binding to the Il6 promoter at late LPS phase. IκBζ overexpression increased Il6 early but reduced it late, and Tet2 loss impaired this late repression.
- Tet2 associated with Hdac1/Hdac2 through its core-DSBH domain. Hdac2 binding at the Il6 promoter fell early and returned late; Hdac2 knockdown increased Il6 transcription and histone acetylation at 10 h, with Hdac1 compensation by 12 h. Catalytically mutant Tet2 still repressed Il6, and Tet2 loss reduced Hdac2 binding and late histone deacetylation.
Methods
- Mouse models included C57BL/6, Tet2fl/fl, Tet2-deficient, and Lyz2-Cre myeloid-specific Tet2-deficient mice; human monocytes came from healthy donors. Cells studied included BMDC, BMM, peritoneal macrophages, and splenic T, B, and NK cells, with LPS at 100 ng/ml; in vivo models were endotoxin shock and DSS colitis.
- Assays included RNA-seq, qPCR, ELISA, immunoblot, immunoprecipitation, co-IP with LC-MS/MS, ChIP and re-ChIP, luciferase reporters, siRNA knockdown, overexpression, and a GAL4-based recruitment assay.
- Statistics used unpaired Student’s t-tests with *P < 0.05 and P < 0.01; error bars were s.e.m. or s.d.; data were from triplicate technical or biological replicates and representative of three independent experiments.
Limitations
- The paper states that animal studies did not randomize by weight or sex and did not use blinding, and that sample size was not predetermined by a statistical method. It also states that HEK293T cells were not authenticated or tested for mycoplasma.
- Evident from the text: Hdac2 knockdown effects were transient because Hdac1 appeared to compensate by 12 h, complicating conclusions about Hdac2-specific repression.
- Evident from the text: many mechanistic experiments relied on overexpression or siRNA in HEK293T or primary cells, and the in vivo work used two inflammatory models; the authors note that additional Tet2-repressed mediators may exist in tissue-resident immune cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 16 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“MS-275 strongly inhibits Hdac1/2 over Hdac3 (ref. 19)”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
What the sources say
- Supportedcites [19] Inoue S Mai A Dyer MJ Cohen GM Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006 66 6785 6792 16818655 source
In the Results section 'Expression of HDACs in CLL cells and various cell lines', our copy reports that MS-275 (1-2.5 micromol/L) inhibited HDAC1 and HDAC2 activities by ~50-70% whereas 1 micromol/L did not inhibit HDAC3 (~20% only at 2.5 micromol/L), and explicitly frames the experiment as confirming that 'MS-275 was selectively inhibiting HDAC1 and HDAC2 rather than HDAC3'. The same section also states MS-275 preferentially inhibits HDAC1 (IC50 ~0.3 micromol/L) versus HDAC3 (IC50 ~8 micromol/L), though that IC50 comparison is itself credited to ref. 32; the paper's own immunoprecipitation/activity data carry the claim. Thus the paraphrase 'strongly inhibits Hdac1/2 over Hdac3' matches what this source attributes to MS-275. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overexpressed Tet2 recruited more endogenous Hdac2 to the Il6 promoter”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Attenuated histone deacetylation in Tet2-deficient cells was also observed at late phase during LPS response”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of Tet2 caused higher expression of IFN-γ in activated CD8+ T cells”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of Tet2 barely affects TLR4 signalling pathways”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 103 claims and to verify the 15 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 28
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mice deficient in Tet2 developed more severe inflammation in several tissues upon challenge with bacterial endotoxin”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this effect on Il6 expression was independent of the catalytic function of Tet2”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TET2, an enzyme that catalyzes DNA demethylation, results in prolonged and high expression of proinflammatory cytokines, including IL-6 [180].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results contrast with findings in peripheral macrophages after intraperitoneal injection in vivo (Zhang et al., 2015).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Zhang et al., 2015
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
TET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity
Williams, K., Christensen, J., Pedersen, M. T., Johansen, J. V., Cloos, P. A. C., Rappsilber, J., & Helin, K. (2011) · Nature · doi:10.1038/nature10066 · Cited by 1,021
TETonic shift: biological roles of TET proteins in DNA demethylation and transcription
Pastor, W. A., Aravind, L., & Rao, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3589 · Cited by 897
Ma, F., Xu, S., Liu, X., Zhang, Q., Xu, X., Liu, M., Hua, M., Li, N., Yao, H., & Cao, X. (2011) · Nature Immunology · doi:10.1038/ni.2073 · Cited by 641
Self-citationChromatin modifiers and remodellers: regulators of cellular differentiation
Chen, T., & Dent, S. Y. R. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3607 · Cited by 619
TET2 promotes histone O-GlcNAcylation during gene transcription
Chen, Q., Chen, Y., Bian, C., Fujiki, R., & Yu, X. (2013) · Nature · doi:10.1038/nature11742 · Cited by 511
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS
Deplus, R., Delatte, B., Schwinn, M. K., Defrance, M., Méndez, J., Murphy, N., Dawson, M. A., Volkmar, M., Putmans, P., Calonne, E., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.357 · Cited by 486
Self-citationRegulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ
Yamamoto, M., Yamazaki, S., Uematsu, S., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Kuwata, H., Takeuchi, O., Takeshige, K., et al. (2004) · Nature · doi:10.1038/nature02738 · Cited by 460
Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397
Qiao, Y., Giannopoulou, E. G., Chan, C. H., Park, S.-H., Gong, S., Chen, J., Hu, X., Elemento, O., & Ivashkiv, L. B. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.009 · Cited by 330
Ichiyama, K., Chen, T., Wang, X., Yan, X., Kim, B.-S., Tanaka, S., Ndiaye-Lobry, D., Deng, Y., Zou, Y., Zheng, P., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.005 · Cited by 327
Chen, W., Han, C., Xie, B., Hu, X., Yu, Q., Shi, L., Wang, Q., Li, D., Wang, J., Zheng, P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.011 · Cited by 276
Self-citationRampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.004 · Cited by 261
Self-citationXia, M., Liu, J., Wu, X., Liu, S., Li, G., Han, C., Song, L., Li, Z., Wang, Q., Wang, J., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.016 · Cited by 167
Self-citationLiu, J., Han, C., Xie, B., Wu, Y., Liu, S., Chen, K., Xia, M., Zhang, Y., Song, L., Li, Z., et al. (2014) · Nature Immunology · doi:10.1038/ni.2898 · Cited by 128
Self-citationInoue, S., Mai, A., Dyer, M. J. S., & Cohen, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4563 · Cited by 120
IκBζ Is a Transcriptional Key Regulator of CCL2/MCP-1
Hildebrand, D. G., Alexander, E., Hörber, S., Lehle, S., Obermayer, K., Münck, N.-A., Rothfuss, O., Frick, J.-S., Morimatsu, M., Schmitz, I., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300089 · Cited by 94
Class-specific Regulation of Pro-inflammatory Genes by MyD88 Pathways and IκBζ
Kayama, H., Ramirez-Carrozzi, V. R., Yamamoto, M., Mizutani, T., Kuwata, H., Iba, H., Matsumoto, M., Honda, K., Smale, S. T., & Takeda, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709965200 · Cited by 92
Involvement of Innate Immunity in the Development of Inflammatory and Autoimmune Diseases
TLASKALOVÁ-HOGENOVÁ, H., TUCKOVÁ, L., STEPÁNKOVÁ, R., HUDCOVIC, T., PALOVÁ-JELÍNKOVÁ, L., KOZÁKOVÁ, H., ROSSMANN, P., SANCHEZ, D., CINOVÁ, J., HRNČÍŘ, T., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.122 · Cited by 68
Liu, Y., Zhang, Q., Ding, Y., Li, X., Zhao, D., Zhao, K., Guo, Z., & Cao, X. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402087 · Cited by 61
Self-citationClass-specific regulation of pro-inflammatory genes by MyD88 pathways and IκBζ.
Kayama, H., Ramirez-Carrozzi, V. R., Yamamoto, M., Mizutani, T., Kuwata, H., Iba, H., Matsumoto, M., Honda, K., Smale, S. T., & Takeda, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.a114.709965 · Cited by 31
Cited by
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
“Previous studies showed that activated STAT3 proteins could promote cytokine production in a variety of cancers.(244) Using a JAK2 inhibitor to treat mice with MPN resulted in reduced cytokine levels and attenuated systemic symptoms.”
BackgroundMacrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
“Similarly, TET deficiency by modulating DNA methylation and hydroxymethylation for activating macrophages with high IL-6 and IL-1B expression is also documented.(230) Leishmania donovani infection induces methylation changes at the 443 CpG site in host macrophages, suppressing innate immunity and thereby enabling path…”
BackgroundTransition from inflammation to proliferation: a critical step during wound healing
Landén, N. X., Li, D., & Ståhle, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2268-0 · Cited by 1,980
TET-mediated active DNA demethylation: mechanism, function and beyond
Wu, X., & Zhang, Y. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.33 · Cited by 1,661
Metadata
- Authors
- Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., Su, X., Liu, J., Ge, W., Levine, R. L., Li, N., & Cao, X.
- Affiliations
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Cao, Xuetao
- ORCID
- Venue
- Nature
- Published
- 2015-08-19
- Volume
- 525
- Issue
- 7569
- Pages
- 389-393
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4697747
- OpenAlex
- W1171241794
- Cited by
- 807
- References
- 30
- Citations by year
- 2026: 56 · 2025: 77 · 2024: 83 · 2023: 89 · 2022: 93 · 2021: 82 · 2020: 79 · 2019: 85 · 2018: 62 · 2017: 50 · 2016: 43 · 2015: 7
- FWCI
- 23.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA173636, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- TET2, HDAC2, interleukin-6, inflammation resolution, histone deacetylation, transcriptional repression, 5-hydroxymethylcytosine, IκB, lipopolysaccharide, dendritic cells, macrophages, endotoxic shock, DSS-induced colitis
- MeSH terms
- Interleukin-6 Inhibitors, Acetylation, Animals, Chromatin, Colitis, Dendritic Cells, DNA-Binding Proteins, Female, Histones, Humans, Inflammation, Macrophages, Male, Mice, Inbred C57BL, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription, Genetic, Down-Regulation, Interleukin-6, DNA Methylation, I-kappa B Proteins, Epigenesis, Genetic, Dioxygenases, Mice, Histone Deacetylase 2, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.